PIPELINE

Global Leader of Cancer Treatments

Pipeline

New drug & Hybrid New Drug candidates that exhibit a pharmacological synergistic effect discovered using A-SAM solution

table of pipeline
Project Class Characteristics Development Status
ATB-
301
Immuno-Oncology New drug Project supported by TIPS (2018.08~2020.07)
MFDS Pharm-Navi
(2019.04~)
<Combination therapy synergistic effect>
Efficacy test
In-vitro / in-vivo
ATB-
302
Immuno-Oncology New drug <Combination therapy synergistic effect> In-vitro efficacy study stage
ATB-
310
Targeted Therapy In-vitro efficacy study stage
ATB-
101
Diabetes/Hypertension
Hybrid New Drug
Project supported by Government
(2017.11~2018.12)
<synergistic effect>
Formulation
Pharmacology
Toxicity
Completed
Progress in scale-up
ATB-
210
Pain Hybrid New Drug <synergistic effect> Formulation study
ATB-
410
Geriatric disease Hybrid New Drug Worldwide
<Synergistic effect>
Formulation completion
ATB-
501
CNS disease Hybrid New Drug <Synergistic effect> Formulation study